ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 729-732

  Caliò, Anna ^a   Nottegar, Alessia ^a   Gilioli, Eliana ^a   Bria, Emilio ^a   Pilotto, Sara ^a   Peretti, Umberto ^a   Kinspergher, Stefania ^a   Simionato, Francesca ^a   Pedron, Serena ^a   Knuutila, Sakari ^b   Tortora, Giampaolo ^a   Eccher, Albino ^a   Santo, Antonio ^a   Tondulli, Luca ^a   Inghirami, Giorgio ^c   Tabbò, Fabrizio ^c   Martignoni, Guido ^a   Chilosi, Marco ^a   Scarpa, Aldo ^a   Brunelli, Matteo ^a  

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Anaplastic lymphoma kinase rearrangement; Break apart fluorescence in situ hybridization; Dual color fluorescence in situ hybridization; Squamous cell carcinoma; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; EML4-ALK FUSION PROTEIN, HUMAN; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SOX2 PROTEIN, HUMAN; THYROID NUCLEAR FACTOR 1; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CYTOGENETICS; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; CHEMISTRY; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

AGED; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-5; KERATIN-6; KERATIN-7; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899105477     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000109     Document Type: Article

References (15)

1. Lindeman NI Cagle PT Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.
2. Alrifai D Popat S Ahmed M et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer 2013;80:339-340.
3. Kim H Park E Kim YJ Chung JH. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement. Virchows Arch 2013;462:597-599.
4. Ochi N Yamane H Yamagishi T Takigawa N Monobe Y. Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene Lung Cancer 2013;79:94-95.
5. Klempner SJ Cohen DW Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol 2011;6:1439-1440.
6. Chaft JE Rekhtman N Ladanyi M Riely GJ. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol 2012;7:768-769.
7. Gainor JF Varghese AM Ou SH et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-4281.
8. Kwak EL Bang YJ Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
9. Rikova K Guo A Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
10. Soda M Choi YL Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
11. Seto T Kiura K Nishio M et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm open-label phase 1-2 study. Lancet Oncol 2013;14:590-598.
12. Camidge DR Bang YJ Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
13. Boland JM Erdogan S Vasmatzis G et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-1158.
14. Paik PK Varghese AM Sima CS et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535-2540.
15. Shukuya T Takahashi T Kaira R et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011;102:1032-1037.